Spring may finally be here for multinationals looking for a smoother development path for their new drugs in China.
Just days after the head of the country’s drug review and approval agency expressed publicly a willingness to welcome more foreign drugs into China, a new draft regulation that promises...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?